Clinical Trial Update: CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating CAPOX plus bevacizumab and tislelizumab in first-line advanced gastroesophageal adenocarcinoma with PD-L1 CPS < 5 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Adenocarcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Advanced Gastroesophageal Adenocarcinoma, First-line Therapy | Phase 2 | Status: COMPLETED